mTOR通路在调控造血干细胞自我更新和分化中的研究进展*

doi:10.3969/j.issn.1671-2587.2024.06.018

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (6): 818-824.DOI: 10.3969/j.issn.1671-2587.2024.06.018

mTOR通路在调控造血干细胞自我更新和分化中的研究进展^*

王嘉琪¹, 肖军², 李翠莹^1,2

¹河北北方学院,河北张家口 075000;
²空军军医大学空军特色医学中心输血科,北京 100142

收稿日期:2024-07-01 出版日期:2024-12-20 发布日期:2024-12-20
通讯作者: 李翠莹,主要从事临床输血及免疫血液学研究工作,（E-mail）licuiying2013@qq.com。
作者简介:王嘉琪,主要从事临床检验诊断学及临床输血学研究工作,（E-mail）15832303086@163.com。
基金资助:
*本课题受空军军医大学效能提升项目（No.2021HKYX15）、空军特色医学中心青年人才项目（No.22BJQN009）资助

Research Progress of mTOR Pathway in Regulating Self-renewal and Differentiation of Hematopoietic Stem Cells

WANG Jiaqi¹, XIAO Jun², LI Cuiying^1,2

¹Graduate School of Hebei North University, Zhangjiakou, Hebei Province 075000;
²Department of Blood Transfusion, Air Force Medical Center, Beijing 100142

Received:2024-07-01 Online:2024-12-20 Published:2024-12-20

摘要/Abstract

摘要： 哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin, mTOR）是一种丝/苏氨酸蛋白激酶,在调节细胞的生长、增殖中起着重要的作用。mTOR复合体通过磷酸化激活下游底物S6K1、4E-BP等调节细胞生长、增殖、蛋白质代谢等等,同样mTOR信号通路在造血系统中也发挥重要作用,其整合多种信号对造血干细胞的静止、自我更新和多向分化三个过程起调节作用,本文系统介绍相关信号分子及蛋白如何通过影响mTOR信号通路并进一步影响造血干细胞发挥功能。

关键词: 造血干细胞, mTOR信号通路, 造血分化, 自我更新, 恶性造血

Abstract: The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that plays an important role in regulating cell growth, proliferation.The mTOR complex regulates cell growth, proliferation, protein metabolism by phosphorylating and activating downstream substrates such as S6K1, 4E-BP, etc. The mTOR signalling pathway similarly plays an important role in the haematopoietic system, integrating multiple signals to regulate the three processes of haematopoietic stem cell quiescence, self-renewal and multidirectional differentiation.This article systematically describes how relevant signalling molecules and proteins affect the mTOR signalling pathway and further influence haematopoietic stem cell function.

Key words: Haematopoietic stem cells, mTOR signalling pathway, Haematopoietic differentiation, Self-renewal, Malignant haemopoiesis

中图分类号:

R457

王嘉琪, 肖军, 李翠莹. mTOR通路在调控造血干细胞自我更新和分化中的研究进展^*[J]. 临床输血与检验, 2024, 26(6): 818-824.

WANG Jiaqi, XIAO Jun, LI Cuiying. Research Progress of mTOR Pathway in Regulating Self-renewal and Differentiation of Hematopoietic Stem Cells[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 818-824.

参考文献

[1] OGAWA M.Differentiation and proliferation of hematopoietic stem cells[J]. Blood,1993,81(11):2844-2853.
[2] ROSSI D J,SEITA J,CZECHOWICZ A,et al.Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging[J]. Cell Cycle,2007,6(19):2371-2376.
[3] DZIERZAK E,BIGAS A.Blood development: hematopoietic stem cell dependence and independence[J].Cell Stem Cell,2018,22(5):639-651.
[4] LEE D H,KIM T S,LEE D J,et al.Mammalian sterile 20 kinase 1 and 2 are important regulators of hematopoietic stem cells in stress condition[J]. Sci Rep,2018,8(1):942.
[5] WU F,CHEN Z,LIU J B,et al.The Akt-mTOR network at the interface of hematopoietic stem cell homeostasis[J]. Exp Hematol,2021,103:15-23.
[6] HO A D.Kinetics and symmetry of divisions of hematopoietic stem cells[J]. Exp Hematol, 2005,33(1):1-8.
[7] YANG L P,BRYDER D,ADOLFSSON J,et al.Identification of Lin (-) Sca1(+)kit(+)CD34+Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients[J]. Blood,2005,105(7):2717-2723.
[8] CHENG H,ZHENG Z F,CHENG T.New paradigms on hematopoietic stem cell differentiation[J]. Protein Cell,2020,11(1):34-44.
[9] SPEVAK C C,ELIAS H K,KANNAN L,et al. Hematopoietic stem and progenitor cells exhibit stage-specific translational programs via mTOR- and CDK1-dependent mechanisms[J]. Cell Stem Cell,2020,26(5):755-765.e7.
[10] GUO F K,ZHANG S M,GROGG M,et al.Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis[J]. Haematologica,2013,98(9):1353-1358.
[11] MALIK N,SANSOM O J,MICHIE A M.The role of mTOR-mediated signals during haemopoiesis and lineage commitment[J]. Biochem Soc Trans, 2018, 46(5):1313-1324.
[12] QIAN P X,HE X C,PAULSON A,et al.The Dlk1-Gtl2 locus preserves LT-HSC function by inhibiting the PI3K-mTOR pathway to restrict mitochondrial metabolism[J]. Cell Stem Cell,2016,18(2):214-228.
[13] VAN GALEN P,KRESO A,WIENHOLDS E,et al.Reduced lymphoid lineage priming promotes human hematopoietic stem cell expansion[J]. Cell Stem Cell, 2014,14(1):94-106.
[14] FINGAR D C,BLENIS J.Target of rapamycin (TOR):an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression[J]. Oncogene,2004,23(18):3151-3171.
[15] WEICHHART T. mTOR as regulator of lifespan, aging, and cellular senescence:a mini-review[J]. Gerontology, 2018,64(2):127-134.
[16] JHANWAR-UNIYAL M,WAINWRIGHT J V,MOHAN A L,et al.Diverse signaling mechanisms of mTOR complexes:mTORC1 and mTORC2 in forming a formidable relationship[J]. Adv Biol Regul,2019,72:51-62.
[17] SAXTON R A,SABATINI D M. mTOR signaling in growth, metabolism, and disease[J]. Cell,2017,168(6): 960-976.
[18] MANNING B D,TOKER A.AKT/PKB signaling: navigating the network[J]. Cell,2017,169(3):381-405.
[19] JACINTO E,LOEWITH R,SCHMIDT A,et al.Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive[J]. Nat Cell Biol,2004,6(11):1122-1128.
[20] IKENOUE T,INOKI K,YANG Q,et al.Essential function of TORC2 in PKC and Akt turn motif phosphorylation,maturation and signalling[J]. EMBO J, 2008,27(14):1919-1931.
[21] HOSHII T,MATSUDA S,HIRAO A.Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis[J]. J Biochem,2014,156(2):73-83.
[22] WU X L,WANG L K,YANG D D,et al.Effects of Glut1 gene silencing on proliferation,differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway[J]. J Cell Biochem, 2018,119(2):2356-2367.
[23] SHARIF O,BRUNNER J S,VOGEL A,et al.Macrophage rewiring by nutrient associated PI3K dependent pathways[J]. Front Immunol,2019,10:2002.
[24] SARRAZY V,VIAUD M,WESTERTERP M,et al.Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE (-/-) mice[J]. Circ Res, 2016, 118(7):1062-1077.
[25] ALBERT B,TOMASSETTI S,GLOOR Y,et al.Sfp1 regulates transcriptional networks driving cell growth and division through multiple promoter-binding modes[J]. Genes Dev,2019,33(5/6):288-293.
[26] SAKI N,JALALIFAR M A,SOLEIMANI M,et al.Adverse effect of high glucose concentration on stem cell therapy[J]. Int J Hematol Oncol Stem Cell Res, 2013,7(3):34-40.
[27] CHEN X,YU C Y,LIU X H,et al.Intracellular galectin-3 is a lipopolysaccharide sensor that promotes glycolysis through mTORC1 activation[J]. Nat Commun, 2022, 13(1):7578.
[28] CHUNG J,BAUER D E,GHAMARI A,et al. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability[J]. Sci Signal, 2015,8(372):ra34.
[29] OBUROGLU L,ROMANO M,TAYLOR N,et al.Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation[J]. Curr Opin Hematol,2016,23(3):198-205.
[30] ITO K,CARRACEDO A,WEISS D,et al.A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance[J]. Nat Med,2012,18(9):1350-1358.
[31] KALAITZIDIS D,SYKES S M,WANG Z,et al.mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis[J]. Cell Stem Cell, 2012,11(3):429-439.
[32] MAGEE J A,IKENOUE T,NAKADA D,et al.Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression[J]. Cell Stem Cell,2012,11(3):415-428.
[33] MONSALVE A,CANALS I,OBUROGLU L.FOXO1 regulates pentose phosphate pathway-mediated induction of developmental erythropoiesis[J]. Front Cell Dev Biol,2022,10:1039636.
[34] CAPITANO M L,BROXMEYER H E.A role for intracellular and extracellular DEK in regulating hematopoiesis[J]. Curr Opin Hematol,2017,24(4):300-306.
[35] CHEN Z,HUO D W,LI L,et al.Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis[J]. J Exp Med,2021,218(5): e20201974.
[36] LIANG R,ARIF T,KALMYKOVA S,et al. Restraining lysosomal activity preserves hematopoietic stem cell quiescence and potency[J]. Cell Stem Cell,2020,26(3): 359-376.e7.
[37] LIU L,INOKI A,FAN K,et al.ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity[J]. Blood,2020, 136(26):2975-2986.
[38] BUITENHUIS M,COFFER P J.The role of the PI3K-PKB signaling module in regulation of hematopoiesis[J]. Cell Cycle,2009,8(4):560-566.
[39] ZHANG J W,GRINDLEY J C,YIN T,et al.PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention[J]. Nature,2006, 441(7092):518-522.
[40] ZHENG L,PAN C,TIAN W L,et al.Atp8a1 deletion increases the proliferative activity of hematopoietic stem cells by impairing PTEN function[J]. Cell Oncol,2023, 46(4):1069-1083.
[41] CHEN C,LIU Y,LIU R H,et al.TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species[J]. J Exp Med,2008,205(10):2397-2408.
[42] SIEGEMUND S,RIGAUD S,CONCHE C,et al.IP3 3-kinase B controls hematopoietic stem cell homeostasis and prevents lethal hematopoietic failure in mice[J]. Blood,2015,125(18):2786-2797.
[43] LIU Q,LUO L H,REN C H,et al.The opposing roles of the mTOR signaling pathway in different phases of human umbilical cord blood-derived CD34+ cell erythropoiesis[J]. Stem Cells,2020,38(11):1492-1505.
[44] PENG H,KASADA A,UENO M,et al.Distinct roles of Rheb and Raptor in activating mTOR complex 1 for the self-renewal of hematopoietic stem cells[J]. Biochem Biophys Res Commun,2018,495(1):1129-1135.
[45] WANG X M,GAO Y N,GAO J,et al.Rheb1 loss leads to increased hematopoietic stem cell proliferation and myeloid-biased differentiation in vivo[J]. Haematologica, 2019,104(2):245-255.
[46] BUECHLER M B,AKILESH H M,HAMERMAN J A.Cutting edge:direct sensing of TLR7 ligands and type Ⅰ IFN by the common myeloid progenitor promotes mTOR/PI3K-dependent emergency myelopoiesis[J]. J Immunol,2016,197(7):2577-2582.
[47] BONO C,GUERRERO P,ERADES A,et al.Direct TLR2 signaling through mTOR and TBK1 induces C/EBPβ and IRF7-dependent macrophage differentiation in hematopoietic stem and progenitor cells[J]. Stem Cells, 2022,40(10):949-962.
[48] TROWBRIDGE J J,XENOCOSTAS A,MOON R T,et al.Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation[J]. Nat Med,2006, 12(1):89-98.
[49] KAO C Y,JIANG J L,THOMPSON W,et al.MiR-486-5p and miR-22-3p enable megakaryocytic differentiation of hematopoietic stem and progenitor cells without thrombopoietin[J]. Int J Mol Sci,2022,23(10):5355.
[50] YAMASHITA M,DELLORUSSO P V,OLSON O C,et al.Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer,2020, 20(7):365-382.
[51] LIU H C,HUSSAIN Z,XIE Q Q,et al.Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax[J]. Exp Cell Res,2022,417(2): 113192.
[52] OSMAN N,ELZAYAT R,ELTOUNSI I.Higher mTOR expression:a marker of poor outcome in patients with de novo AML[J]. Indian J Hematol Blood Transfus,2023, 39(2):325-329.
[53] FENG Y H,WU L S. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival[J]. Biochem Biophys Res Commun,2017,483(2):897-903.
[54] ANNUNZIATA M,BONIFACIO M,BRECCIA M,et al.Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia[J]. Front Oncol,2020,10:883.
[55] LY C,ARECHIGA A F,MELO J V,et al.Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin[J]. Cancer Res, 2003,63(18):5716-5722.
[56] CARAYOL N,VAKANA E,SASSANO A,et al.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells[J]. Proc Natl Acad Sci U S A,2010,107(28):12469-12474.
[57] CHU S H,HEISER D,LI L,et al.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm[J]. Cell Stem Cell,2012,11(3):346-358.
[58] PALUMBO G A,STELLA S,PENNISI M S,et al.The role of new technologies in myeloproliferative neoplasms[J]. Front Oncol,2019,9:321.
[59] BARTALUCCI N,TOZZI L,BOGANI C,et al.Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms[J]. J Cell Mol Med,2013,17(11):1385-1396.
[60] DAL COL J,ZANCAI,TERRIN L,et al.Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma[J]. Blood,2008, 111(10):5142-5151.

mTOR通路在调控造血干细胞自我更新和分化中的研究进展^*

Research Progress of mTOR Pathway in Regulating Self-renewal and Differentiation of Hematopoietic Stem Cells

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	明静, 丁凯阳, 胡茂贵, 王馨辰. 阿伐曲泊帕联合rhTPO在恶性血液病自体造血干细胞移植中的临床疗效分析^*[J]. 临床输血与检验, 2024, 26(6): 812-817.
[2]	童欣欣, 钟明璐, 黄慧瑛, 邓晖, 黄建云, 魏亚明. 血液病患者异基因造血干细胞移植后Rh血型转变研究^*[J]. 临床输血与检验, 2024, 26(2): 230-235.
[3]	张成鑫, 杨杰, 郝欣欣, 王秋实. 单中心自体造血干细胞采集效果影响因素分析^*[J]. 临床输血与检验, 2024, 26(1): 55-59.
[4]	异基因造血干细胞移植临床输血专家共识起草专家组. 异基因造血干细胞移植临床输血专家共识[J]. 临床输血与检验, 2023, 25(5): 586-593.
[5]	卓海龙, 邵春燕, 骆群. 体外模拟A型/O型不同比例混合红细胞对血型抗原鉴定的影响^*[J]. 临床输血与检验, 2023, 25(4): 475-479.
[6]	孙秋爽, 梁卉. 行异基因造血干细胞移植治疗的伴严重血小板减少的儿童MYH9相关疾病1例并文献复习[J]. 临床输血与检验, 2023, 25(4): 544-548.
[7]	樊凤艳, 马越云. RhD血型不匹配异基因造血干细胞移植输血RhD血型选择[J]. 临床输血与检验, 2023, 25(2): 189-192.
[8]	朱灿, 陈立, 杨振兴, 张根玲, 苗莹莹, 李忠俊. 思维导图在外周血造血干细胞供者单采术前宣教中的应用探讨^*[J]. 临床输血与检验, 2022, 24(6): 803-806.
[9]	王倩, 杨李辉, 丁天凌, 夏荣. 自体造血干细胞移植中不同预处理方案与血小板输注的临床分析^*[J]. 临床输血与检验, 2021, 23(6): 686-692.
[10]	高瞻, 肖军, 李小薇, 李翠莹. 低氧诱导因子HIF-2α调控红细胞生成的研究进展*[J]. 临床输血与检验, 2021, 23(5): 561-564.
[11]	富浩轩, 付华来, 王捷, 邓刚. 气相液氮罐内温度差异对脐带血造血干细胞保存质量的影响[J]. 临床输血与检验, 2021, 23(1): 50-54.
[12]	吴月, 朱小玉, 刘会兰, 宋闿迪, 汤宝林, 孙自敏. 强化清髓单份非血缘脐血移植治疗FLT3-ITD突变阳性急性髓系白血病疗效观察^*[J]. 临床输血与检验, 2020, 22(6): 627-632.
[13]	马春娅, 孙晓琳, 封彦楠, 张晓娟, 姜旭, 于洋, 汪德清. 造血干细胞移植患者红细胞输血效果的影响因素分析^*[J]. 临床输血与检验, 2019, 21(4): 341-344.
[14]	周循, 刘小倩, 朱娜娜, 郭建荣. 输血与造血干细胞相关的研究进展^*[J]. 临床输血与检验, 2019, 21(3): 330-332.
[15]	王嘉怡, 黄儒霖, 梁志敏. COM.TEC血细胞分离机在儿童外周血干细胞采集中的应用[J]. 临床输血与检验, 2018, 20(5): 496-499.